However, PCa eventually escapes its response to hormone therapies and progresses to ENZ/ABI-resistant CRPC by developing multiple mechanisms including expression of constitutively active AR-Vs lacking the LBD, especially AR-V7 1-5. The gene discussed is AR; the disease is posterior cortical atrophy.